Sodium Selenate Treatment for Probable Behavioural Variant Fronto-temporal Dementia

Subject area of study: Behavioural Variant Fronto-temporal Dementia

Title of study:
Sodium Selenate Treatment for Probable Behavioural Variant Fronto-temporal Dementia

Brief outline of the study:
This research project is looking at whether the trial drug, sodium selenate decreases the rate of brain shrinkage in patients with behavioural variant Fronto-temporal dementia (bvFTD). Participants are randomly assigned to one of two groups. One group will receive the study drug, sodium selenate, and the other group will receive a placebo.

Participation in this research involves attending appointments at the study doctor’s clinic up to ten times over 15 months, taking the study drug (or placebo) three times a day and maintaining a Diary Card (recording any side effects or medication changes).

The appointments will include MRI & PET scans, two lumbar punctures, physical & neurological examinations, blood tests, and cognitive tests & questionnaires.

We are currently recruiting participants with bvFTD to take part in this study across four sites, three in Melbourne and one in Sydney.

Department: Neuroscience
Recruitment start date: Sun, 04/04/2021
Recruitment end date: Tue, 01/07/2025
Contact person title: Dr
Contact person first name: Lucy
Contact person last name: Vivash
Contact email: selenate@alfred.org.au
Contact phone number: (03) 9903 0860
Website link: https://www.monash.edu/medicine/ccs/neuroscience/home
Ethics Committee Project Number: 609/19
Do you have advertising approval?: Yes
Approved by: Alfred